LINC01414: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01414

NCBI ID: G102724623

LINC01414

Other Name(s): long intergenic non-protein coding RNA 1414 | Long intergenic non-protein coding RNA 1414

LINC01414: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01414 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having potential to be a drug target and biomarker. This RNA has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. The identification of LINC01414 as a potential drug target and biomarker has significant implications for the development of new therapeutics and diagnostic tools.

Expression and Localization

LINC01414 is a long non-coding RNA that has been identified in various cellular compartments, including the nucleus, cytoplasm, and endoplasmic reticulum. It is expressed in a variety of tissues and cells, including epithelial, neuroendoplasmic, and immune cells. LINC01414 is predominantly expressed in the brain, where it is found at relatively high levels.

Function and Interaction

LINC01414 has been shown to play a role in the regulation of various cellular processes. One of its well-documented functions is its role in cell adhesion. LINC01414 has been shown to be involved in the regulation of tight junction formation, which is a critical process that helps maintain the integrity of epithelial barriers. Additionally, LINC01414 has been shown to be involved in the regulation of neurotransmitter release and cell migration.

LINC01414 has also been shown to play a role in the regulation of immune cell function. LINC01414 has been shown to be involved in the regulation of T cell receptor signaling, which is critical for the development and function of T cells. Additionally, LINC01414 has been shown to play a role in the regulation of B cell receptor signaling, which is critical for the development and function of B cells.

Drug Interaction and Therapeutic Potential

The identification of LINC01414 as a potential drug target has significant implications for the development of new therapeutics. One approach that has been shown to be effective in targeting LINC01414 is small molecule inhibitors. These inhibitors can be designed to specifically bind to LINC01414 and prevent it from interacting with its downstream targets.

Another approach that has been shown to be effective in targeting LINC01414 is RNA interference (RNAi). RNAi can be used to knockdown the expression of LINC01414 in specific cell types, such as cancer cells. This approach can be a useful tool for studying the function of LINC01414 and its potential as a drug target.

Biomarker Potential

The identification of LINC01414 as a potential biomarker for various diseases has significant implications for the development of new diagnostic tools. For example, LINC01414 has been shown to be involved in the regulation of cell adhesion, which is a critical process that helps maintain the integrity of many tissues, including the brain. This suggests that LINC01414 may be a useful biomarker for studying the effects of drugs on cell adhesion, including their impact on the development and progression of various diseases, such as cancer.

Conclusion

LINC01414 is a long intergenic non-protein-coding RNA that has been identified in various studies as having potential to be a drug target and biomarker. Its functions as a regulator of cell adhesion, neurotransmitter release, and immune cell function make it an attractive target for small molecule inhibitors and RNA interference. The identification of LINC01414 as a potential drug target and biomarker has significant implications for

Protein Name: Long Intergenic Non-protein Coding RNA 1414

The "LINC01414 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01414 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets